Bavarian Nordic Receives $1.6-Billion Contract from HHS
ePT--the Electronic Newsletter of Pharmaceutical Technology
Kvistgard, Denmark (June 4)-Bavarian Nordic received a $1.6-billion contract from the US Department of Health and Human Services to manufacture and deliver 20 million doses of its smallpox vaccine "Imvamune."
Kvistgård, Denmark (June 4)-Bavarian Nordic received a $1.6-billion contract from the US Department of Health and Human Services (HHS, Washington, DC) to manufacture and deliver 20 million doses of its smallpox vaccine “Imvamune.”
HHS is supplying a base contract payment of $500 million to support additional research and development of Imvamune for the vaccine’s potential use during an emergency. The payment also will fund nonclinical and clinical studies for the vaccine.
The contract includes advance and milestone payments worth as much as $150 million and contractual options worth $1.1 billion. The contractual-options payment would fund further clinical studies of the vaccine that extend the license to include those infected with HIV, children, and the elderly. The payment also could be used to procure up to 60 million additional doses of Imvamune.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
INTERPHEX 2025: Use of Walk-In Chambers for Bio/Pharma Development and Manufacturing
April 2nd 2025Sitting down with the PharmTech Group at INTERPHEX 2025, Christopher Murphy, director of Global Business Development and Service Customer Support at Environmental Specialties, discusses the design and critical role of walk-in chambers in the bio/pharmaceutical industry.
